BWXT Reports Solid Second Quarter 2018 Results with Strong Revenue Growth
Highlights • 2Q18 strong revenue growth of 7%; 2Q18 orders up significantly • 2Q18 GAAP EPS of $0.60; 2Q18 non-GAAP EPS of $0.58 • Reiterated 2018 non-GAAP EPS guidance of $2.45 to $2.55 despite higher interest expense and integration costs • Completed acquisition of Nordion medical isotope business on July 30, 2018 View the full […]
BWXT Names Thomas E. McCabe as Senior Vice President and General Counsel
(LYNCHBURG, Va. – July 23, 2018) – BWX Technologies, Inc. (NYSE:BWXT) announced today that Thomas (Tom) E. McCabe has been named senior vice president, general counsel, chief compliance officer and corporate secretary for BWXT effective July 23, 2018. “We are extremely pleased to welcome Tom to BWXT,” said Rex D. Geveden, president and chief executive […]
BWXT Signs Medical Isotope Development Agreement with Bruce Power
(LYNCHBURG, Va. – July 12, 2018) – BWX Technologies, Inc. (NYSE:BWXT) announced today that a subsidiary has signed an agreement with Bruce Power that will enable the two companies to collaborate on the development and supply of medical isotopes. Under the terms of the agreement, the parties will identify market opportunities for medical isotopes, with […]
BWXT Names John A. Stewart President of Nuclear Fuel Services
(ERWIN, Tenn. – June 28, 2018) – BWX Technologies, Inc. (NYSE:BWXT) announced today that John A. Stewart has been named president of Nuclear Fuel Services, Inc. (NFS) effective July 1, 2018. “John’s impressive history with BWXT and the U.S. Navy make him uniquely suited for this leadership role at NFS,” BWXT Nuclear Operations Group, Inc. […]
BWXT Selects Ontario Power Generation to Provide Irradiation Services for New Medical Isotope Manufacturing Technology
LYNCHBURG, Va. – BWX Technologies, Inc. is expanding its longstanding relationship with Ontario Power Generation (OPG), whose wholly owned subsidiary Canadian Nuclear Partners (CNP) plans to provide irradiation services to support BWXT’s new medical isotope manufacturing technology for molybdenum-99. Earlier this year, BWXT announced that it has developed an innovative and unique process to produce […]
BWXT Names Chris E. Rhodes General Manager of Euclid, Ohio Operations
(EUCLID, OHIO) – BWX Technologies, Inc. (NYSE:BWXT) announced today that Chris E. Rhodes has been named general manager of the BWXT Nuclear Operations Group, Inc. (BWXT NOG) manufacturing facility in Euclid, Ohio. “I am pleased Chris is stepping into this new role after more than two decades with the company,” said BWXT NOG President and […]
BWXT to Present at Morgan Stanley Leveraged Finance Conference
(LYNCHBURG, Va. – June 5, 2018) – BWX Technologies, Inc. (NYSE:BWXT) Senior Vice President and Chief Financial Officer David Black will be presenting at the 2018 Morgan Stanley Leveraged Finance Conference in New Orleans on June 6, 2018. BWXT is a leading supplier of nuclear components, fuel and services to government and commercial customers and […]
BWXT Names Joel W. Duling President of Nuclear Operations Group Subsidiary
(LYNCHBURG, Va. – May 10, 2018) – BWX Technologies, Inc. (NYSE:BWXT) announced today that Joel W. Duling has been appointed to succeed retiring BWXT Nuclear Operations Group, Inc. President Joe G. Henry effective June 22, 2018. Currently, Duling serves as President of BWXT subsidiary Nuclear Fuel Services, Inc. in Erwin, Tennessee. He has nearly 30 […]
BWXT Announces Breakthrough Medical Isotope Manufacturing Technology
BWX Technologies, Inc. (NYSE:BWXT) (“BWXT” or the “Company”) announced today that it has developed an innovative and unique process to manufacture molybdenum-99 (Mo-99) that will enable a stable, North American supply of this critical diagnostic imaging radionuclide. The Mo-99 produced will be used in newly designed technetium-99m (Tc-99m) generators that are in commercial development at […]
BWX Technologies Reports Robust First Quarter 2018 Results with Strong Revenue Growth
Highlights: • 1Q18 GAAP EPS of $0.66, up 20%; 1Q18 non-GAAP EPS of $0.67, up 22%• Strong revenue growth of 7% with expanding segment margins• Consolidated backlog remains healthy at $3.6 billion• Reiterated 2018 guidance: EPS of $2.45 to 2.55; revenue of $1.75 to 1.85 billion View the full release on our Investors Relations page. […]